Europe clamps down on prices of orphan drugs

04/8/2013 | Bloomberg

Cash-strapped European governments have been balking at high prices for drugs to treat rare diseases, sometimes winning significant price concessions from manufacturers. Payers in the U.S. are likely to follow suit, says Mary Dunkle, a vice president at patient advocacy group National Organization for Rare Disorders. Thirteen European Union members are considering a plan to collaborate on cost-benefit analyses of orphan drugs, which might increase access across Europe, says Richard Bergstrom, director general of the European Federation of Pharmaceutical Industries and Associations.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Principal, Global Compliance Operations
DJO Global
Vista, CA
Executive Vice President-MyHealth First Network
Greenville Health System
Greenville, SC